Invesco Ltd. Boosts Stock Position in Arvinas, Inc. $ARVN

Invesco Ltd. increased its position in shares of Arvinas, Inc. (NASDAQ:ARVN) by 119.4% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 81,747 shares of the company’s stock after purchasing an additional 44,493 shares during the quarter. Invesco Ltd. owned approximately 0.11% of Arvinas worth $574,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of ARVN. GF Fund Management CO. LTD. acquired a new position in shares of Arvinas during the 4th quarter valued at about $28,000. GAMMA Investing LLC raised its holdings in shares of Arvinas by 11,283.8% in the 1st quarter. GAMMA Investing LLC now owns 4,212 shares of the company’s stock valued at $300,000 after purchasing an additional 4,175 shares in the last quarter. CWM LLC raised its holdings in shares of Arvinas by 2,317.5% in the 1st quarter. CWM LLC now owns 7,615 shares of the company’s stock valued at $53,000 after purchasing an additional 7,300 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in Arvinas during the first quarter worth approximately $80,000. Finally, Tema Etfs LLC acquired a new position in Arvinas during the fourth quarter worth approximately $227,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Insider Activity at Arvinas

In other news, CFO Andrew Saik sold 5,700 shares of the company’s stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $7.61, for a total transaction of $43,377.00. Following the completion of the sale, the chief financial officer directly owned 164,401 shares of the company’s stock, valued at $1,251,091.61. This represents a 3.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 4.73% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Leerink Partners reissued a “market perform” rating and issued a $9.00 target price (down previously from $10.00) on shares of Arvinas in a report on Monday, June 2nd. Leerink Partnrs lowered Arvinas from a “strong-buy” rating to a “hold” rating in a report on Sunday, June 1st. UBS Group reduced their price objective on Arvinas from $74.00 to $21.00 and set a “buy” rating on the stock in a research report on Thursday, May 15th. Morgan Stanley lowered their price target on shares of Arvinas from $12.00 to $11.00 and set an “equal weight” rating for the company in a report on Friday, May 9th. Finally, Guggenheim reduced their target price on Arvinas from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Twelve analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, Arvinas presently has an average rating of “Moderate Buy” and a consensus target price of $19.76.

Arvinas Stock Performance

Shares of ARVN stock opened at $7.61 on Friday. Arvinas, Inc. has a 1 year low of $5.90 and a 1 year high of $29.61. The stock has a fifty day moving average of $7.49 and a two-hundred day moving average of $8.56. The firm has a market capitalization of $558.73 million, a PE ratio of -7.53 and a beta of 2.38.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.03. Arvinas had a negative net margin of 19.47% and a negative return on equity of 12.01%. The company had revenue of $22.40 million during the quarter, compared to analyst estimates of $34.42 million. During the same quarter last year, the firm posted ($0.49) EPS. The business’s revenue for the quarter was down 70.7% on a year-over-year basis. Equities research analysts predict that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.